You searched for "treatment"
Risk factors for BC after minimally invasive RNU
Bladder cancer (BC) after radical nephroureterectomy (RNU) has an approximate incidence of 20-50%. This contemporary multicentre study will inform the ongoing debate on risk factors for BC after minimally invasive RNU and how it may be prevented. Three hundred and...
Is Retzius-sparing prostatectomy the way forward?
Urinary incontinence is a common complication of conventional robot-assisted radical prostatectomy (RARP). Retzius-sparing RARP is performed through the pouch of Douglas to avoid destroying the pelvic fascia and the prostate’s anatomical structures. It has shown early favourable results in terms...Femeda Ltd Wins Prestigious Medilink Partnership with Academia Award
Femeda has committed to the first real world clinical trial for a consumer medical device globally to be run in Manchester. Femeda is extending the partnership with engagement of Phd students from...Study confirms UroShield™ device extremely effective as a bacteriostatic agent
UroShield™ is a breakthrough disposable ultrasound device developed to prevent catheter blockages and biofilm formation, resulting in a reduction in Urinary Tract Infections (UTI) and therefore reducing the need for antibiotics, improving patient outcomes and lowering healthcare costs.Rodger wireless bedwetting alarm system NOW available to rent or buy
The Rodger wireless bedwetting alarm has 8 different alarm tones and a volume control. It’s available with a vibrating pad for children that are deep sleepers. We offer the alarm system to...Prostate Cancer UK warns of over 8,600 ‘missing men’ as referrals drop by 52,000
The Covid-19 pandemic has led to around 52,000 (28%) fewer urgent prostate cancer referrals in England alone, according to statistics shared by Prostate Cancer UK. It’s estimated that more than 8,600 fewer men started treatment for...Bladder Scanners from Win Health Medical
Our bladder scanners deliver innovation and quality with tangible benefits to clinicians and patients and unprecedented value to the NHS.Advanced renal tumours
Case 1 A 67-year-old gentleman underwent a CT scan after presenting with visible haematuria and weight loss. His comorbidities include hypertension, type II diabetes mellitis and hypercholesterolaemia. He is a smoker. Figure 1. Figure 2. What do Figures 1 and...Prostate Scotland appoints digital technology leader Peter Proud as new trustee
Prostate Scotland has appointed Peter Proud, Founder and CEO of Edinburgh-based digital technology company Forrit, to its Board of Trustees. Bringing more than 30 years of experience in digital transformation, data, and AI-driven innovation, Peter will support the charity’s work...
The case against omitting systematic biopsy in younger men
In this issue of European Urology, Al-Monajjed et al. report findings from the PROBASE trial, which evaluated prostate cancer (PC) detection in men aged 45–50 years with PSA ≥3ng/ml using both MRI-targeted biopsy (TBx) and systematic biopsy (SBx). Among 525...Is it time for a kidney stress test?
In healthcare, what we measure shapes how we predict outcomes and intervene. For kidney health, traditional tools like estimated glomerular filtration rate (eGFR) provide only a partial picture. Relying solely on eGFR is like judging heart health with a resting...
